{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/san-francisco-bay-area-biotech-advances-phase-i-ii-cancer-immunotherapy-trial-fortrea-0#webpage",
"url": "https://www.fortrea.com/insights/san-francisco-bay-area-biotech-advances-phase-i-ii-cancer-immunotherapy-trial-fortrea-0",
"name": "San Francisco Bay Area biotech advances Phase I-II cancer immunotherapy trial with Fortrea",
"description": "This Fortrea case study explores how Phase I/II cancer immunotherapy trials were supported through integrated oncology development and coordinated early-phase clinical trial operations. The study involved complex immunotherapy clinical development activities requiring cross-functional coordination across oncology operations, patient recruitment, study startup, and clinical trial management functions during early-stage cancer research. The case study highlights challenges related to early-phase immunotherapy development, operational continuity, patient enrollment, and coordination of multiple clinical development activities throughout the study lifecycle. Fortrea supported Phase I/II cancer immunotherapy trials through integrated oncology operational support, patient recruitment activities, and structured clinical development planning designed to strengthen execution across participating study functions. By integrating early-phase oncology development with coordinated immunotherapy trial management and operational support, the approach improved continuity across clinical trial activities and supported progression throughout cancer immunotherapy clinical development"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "San Francisco Bay Area biotech advances Phase I-II cancer immunotherapy trial with Fortrea",
"item": "https://www.fortrea.com/insights/san-francisco-bay-area-biotech-advances-phase-i-ii-cancer-immunotherapy-trial-fortrea-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/san-francisco-bay-area-biotech-advances-phase-i-ii-cancer-immunotherapy-trial-fortrea-0#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/san-francisco-bay-area-biotech-advances-phase-i-ii-cancer-immunotherapy-trial-fortrea-0#webpage"
},
"headline": "Supporting Phase I/II Cancer Immunotherapy Trials Through Integrated Clinical Development | Fortrea Case Study",
"description": "This Fortrea case study explores how Phase I/II cancer immunotherapy trials were supported through integrated oncology development and coordinated early-phase clinical trial operations. The study involved complex immunotherapy clinical development activities requiring cross-functional coordination across oncology operations, patient recruitment, study startup, and clinical trial management functions during early-stage cancer research. The case study highlights challenges related to early-phase immunotherapy development, operational continuity, patient enrollment, and coordination of multiple clinical development activities throughout the study lifecycle. Fortrea supported Phase I/II cancer immunotherapy trials through integrated oncology operational support, patient recruitment activities, and structured clinical development planning designed to strengthen execution across participating study functions. By integrating early-phase oncology development with coordinated immunotherapy trial management and operational support, the approach improved continuity across clinical trial activities and supported progression throughout cancer immunotherapy clinical development",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-03/phase-1-2-cancer-immunotherapy-trial-with-fortrea.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-20",
"dateModified": "2025-03-20",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/phase-1-2-cancer-immunotherapy-trial-with-fortrea.pdf",
"encodingFormat": "application/pdf"
}
}
]
}